Hansa Biopharma AB (publ) (STO:HNSA)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 2.65B |
| Revenue (ttm) | 190.49M |
| Net Income (ttm) | -691.58M |
| Shares Out | 101.76M |
| EPS (ttm) | -7.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 346,704 |
| Average Volume | 421,280 |
| Open | 26.04 |
| Previous Close | 26.02 |
| Day's Range | 25.38 - 27.42 |
| 52-Week Range | 22.82 - 42.98 |
| Beta | 1.64 |
| RSI | 34.89 |
| Earnings Date | Jul 16, 2026 |
About Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune... [Read more]
Financial Performance
In 2025, Hansa Biopharma AB's revenue was 222.27 million, an increase of 29.74% compared to the previous year's 171.32 million. Losses were -534.11 million, -33.84% less than in 2024.
Financial StatementsNews
Hansa Biopharma AB (HNSBF) Q1 2026 Earnings Call Highlights: Navigating Revenue Decline and ...
Hansa Biopharma AB (HNSBF) Q1 2026 Earnings Call Highlights: Navigating Revenue Decline and Strategic Initiatives
Q1 2026 Hansa Biopharma AB Earnings Call Transcript
Q1 2026 Hansa Biopharma AB Earnings Call Transcript
Hansa Biopharma AB Earnings Call Transcript: Q1 2026
Q1 2026 saw a 48% revenue decline year-over-year amid major organizational changes and ongoing volatility in organ allocation. Key clinical milestones and regulatory events are expected in 2026, with early Q2 trends showing improvement and a strengthened financial position following a $30M convertible note.
Hansa Biopharma AB: Hansa Biopharma publishes 2025 Annual and Sustainability Reports
LUND, Sweden, March 26, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ STOCKHOLM: HNSA), today published its Annual and Sustainability Reports for 2025. Peter Nicklin, C...
Hansa Biopharma publishes 2025 Annual and Sustainability Reports
LUND, Sweden, March 26, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ STOCKHOLM: HNSA), today published its Annual and Sustainability Reports for 2025. Peter Nicklin, Chair...
Hansa Biopharma AB Transcript: Leerink Global Healthcare Conference 2026
Phase 3 data for imlifidase in kidney transplant will be presented in June, with strong trial results supporting regulatory progress and a focused U.S. launch strategy. Expansion opportunities include other organ transplants, gene therapy, and a next-gen protease for rare diseases.
Hansa Biopharma AB: PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026
If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. LUND, Sweden, March 4, 2026 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" ...
PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026
If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. LUND, Sweden, March 4, 2026 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or "...
Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA
LUND, Sweden, Feb. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) for imlifidase has be...
Hansa Biopharma AB (STU:24H) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ...
Hansa Biopharma AB (STU:24H) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Developments Amid Challenges
Q4 2025 Hansa Biopharma AB Earnings Call Transcript
Q4 2025 Hansa Biopharma AB Earnings Call Transcript
Hansa Biopharma AB Earnings Call Transcript: Q4 2025
Q4 and full-year revenues surged, driven by strong European sales and strategic execution. Cash runway is secured into 2027 following a major equity raise, with U.S. launch preparations advancing and key regulatory milestones expected in 2026.
Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024. Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting kidney transplantation.
Hansa Biopharma AB: Hansa Biopharma has won the 2025 SwedenBIO Award
LUND, Sweden, Jan. 22, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the company has been awarded the prestigious 2025 SwedenBIO Award. The award ...
Hansa Biopharma has won the 2025 SwedenBIO Award
LUND, Sweden, Jan. 22, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the company has been awarded the prestigious 2025 SwedenBIO Award. The award was ...
Hansa Biopharma AB at JPMorgan Healthcare Conference Transcript
Hansa Biopharma AB at JPMorgan Healthcare Conference Transcript
Hansa Biopharma AB Transcript: 44th Annual J.P. Morgan Healthcare Conference
A novel IgG-cleaving enzyme platform is advancing in kidney transplantation, GBS, and gene therapy, with strong clinical data, growing commercial traction in Europe, and a U.S. launch targeted for late 2026 pending regulatory milestones. U.S. KOLs and European payers show high enthusiasm, and operational improvements are underway.
Hansa Biopharma AB: Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types of i...
Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patients Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immu...
Hansa Biopharma AB Transcript: Jefferies London Healthcare Conference 2025
A novel IgG-cleaving enzyme platform targets highly sensitized kidney transplant patients and rare autoimmune diseases, with a BLA filing planned by year-end and potential U.S. approval by August next year. No late-stage competitors exist, and commercial rollout is well-prepared.
Hansa Biopharma AB Transcript: KOL Event
KOLs highlighted imlifidase's transformative impact for highly sensitized kidney transplant patients, citing robust phase III efficacy and safety data, rapid IgG reduction, and significant improvements in transplant access and outcomes. Rapid adoption and policy changes are anticipated.
Hansa Biopharma AB Transcript: Stifel 2025 Healthcare Conference
Imlifidase enables kidney transplants for highly sensitized patients, with U.S. and EU phase 3 trials supporting regulatory filings and commercial growth. Key catalysts include anti-GBM data, BLA submission, and expanded gene therapy partnerships.
Hansa Biopharma AB (HNSBF) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst Revenue ...
Hansa Biopharma AB (HNSBF) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst Revenue Challenges
Q3 2025 Hansa Biopharma AB Earnings Call Transcript
Q3 2025 Hansa Biopharma AB Earnings Call Transcript
Hansa Biopharma AB Earnings Call Transcript: Q3 2025
Q3 2025 saw lower European sales due to regional challenges, but annual growth remains strong and the U.S. market presents a major opportunity, supported by robust phase III data. Cash position is solid after recent equity raises, and 2026 is expected to bring improved performance.